EOS-215

Anti-TREM2 Antibody

TREM2 and its role in tumor immune evasion mechanisms

TREM2+ macrophages comprise a critical immunosuppressive population that plays a detrimental role in established tumors.1

In cancer, triggering receptor expressed on myeloid cells 2 (TREM2) is overexpressed on tumor-associated macrophages (TAMs) in the tumor microenvironment (TME).1,2

TREM2+ TAMs play a critical role in established tumors, contributing to poor prognosis3-5 and fostering an immunosuppressive TME, which promotes therapy resistance, tumor survival, progression, and metastasis across multiple solid tumors.6

Adapted from Cheng X, et al. Front Immunol. 2021;12:646523.

Targeting TREM2 with an antagonist antibody to selectively block this pro-tumoral macrophage population is a promising approach in oncology.

TCGA, The Cancer Genome Atlas; TPM, transcripts per million; TREM2, triggering receptor expressed on myeloid cells 2; TAM, tumor-associated macrophages; TME, tumor microenvironment.

EOS-215 and its mechanism of action

EOS-215 is designed to reprogram macrophages, resulting in immune activation

EOS-215 is a potent anti-TREM2 antibody that blocks ligand binding,7 disrupting key tumor-supportive functions of TAMs in the TME. By targeting TREM2, EOS-215 reprograms macrophages,7 creating conditions to allow for T cell activation and help overcome resistance to current standards of care.

Adapted from Khantakova D, et al. Vaccines. 2022;10(6):943 and Astuti Y, et al. Nature cancer. 2024;5(5): 774–790.

EOS-215 shifts macrophage pro-tumoral programming

EOS-215 addresses anti-PD-1 resistance

Pirson R, at al. Poster presented at: AACR; Apr 27-30 2025; Chicago.

Abs, absolute; aPD-1, anti-PD-1 therapy; CD, cluster of differentiation; FC, fold change; NK, natural killer; Padj, adjusted probability value; PBS, phosphate-buffered saline; Pval, probability value; PD-1, programmed cell death protein 1; TREM2, triggering receptor expressed on myeloid cells 2; TAM, tumor-associated macrophage; TCM-Mφ, tumor-conditioned media-derived macrophage; TME, tumor microenvironment.

Ongoing clinical trials of EOS-215

iTeos is currently investigating EOS-215 in advanced solid tumors. For more information on this study, please click on the links below:

TRM-010: Phase 1 dose escalation and expansion cohort study of EOS-215 as monotherapy and in combination with pembrolizumab or other anticancer treatments in participants with advanced solid tumors

TRM-010 study schema

www.clinicaltrials.gov/study/NCT06877533

Click to access EOS-215 publication

EOS-215 has demonstrated the ability to reverse the multiple pro-tumoral roles of TREM2+ macrophages driving therapy resistance. This creates the opportunity to explore combinations with standard-of-care therapies.7

  1. Khantakova D, et al. Vaccines. 2022;10(6):943.
  2. Cheng X, et al. Front Immunol. 2021;12:646523.
  3. Mantovani A, et al. Nat. Rev. Clin. Oncol. 2017;14:399–416.
  4. Molgora M, et al. Med. 2021;2:666–681.
  5. Pittet M.J, et al. Nat. Rev. Clin. Oncol. 2022;19:402–421.
  1. Wolf E.M, el al. Front. Oncol. 2022;12:984193.
  2. Pirson R, et al. Poster presented at: AACR; April 27-30 2025; Chicago.
  3. Astuti Y, et al. Nature cancer. 2024;5(5):774-790.